Cardiovascular Outcomes Trials Increasingly Complicated By Missing Data

As regulators and payers alike look for sponsors to conduct large-scale cardiovascular outcomes trials in a variety of settings, the problem posed by missing data is a slippery slope, as recent FDA advisory committee reviews of Brilinta and Avandia showcase

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet